|
|
|
|
||
Re: OncLive: Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin LymphomaJBWIN , am I the only one who sees about $ 20 B in revenues by 2022-2025 with the drugs in the first slide,..That is some slide 14 drugs approval by 2022. Amazing how cheap this stock is, how a big Pharma doesn't make a move, totally flabbergasted by it...We are talking about $30-35B in revenues by 2025 and continuing growth. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
211616 | Re: OncLive: Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin Lymphoma | jim_pd | 0 | 6/28/2017 8:03:42 AM |